Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary E Enama

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Plos One|May 8, 2015
DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trialJulie E Ledgerwood, Abbie R Bellamy, Robert Belshe, et al.
Contemporary Clinical Trials|August 16, 2015
Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boostJulie E Ledgerwood, Zonghui Hu, Pamela Costner, et al.
Plos One|November 16, 2016
Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Michelle C Crank, Eleanor M P Wilson, Laura Novik, et al.
The Journal of Infectious Diseases|September 17, 2014
Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trialUzma N Sarwar, Pamela Costner, Mary E Enama, et al.
The Journal of Infectious Diseases|March 15, 2011
A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trialJulie E Ledgerwood, Theodore C Pierson, Sarah A Hubka, et al.
Vaccine|October 1, 2008
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialJulie E Martin, Mark K Louder, LaSonji A Holman, et al.
Clinical and Vaccine Immunology : CVI|September 22, 2006
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trialJulie E Martin, Nancy J Sullivan, Mary E Enama, et al.
Plos One|September 19, 2019
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trialCristina Carter, Katherine V Houser, Galina V Yamshchikov, et al.
Plos One|November 3, 2018
DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trialKatherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, et al.
Plos One|April 18, 2015
Phase 1 study of pandemic H1 DNA vaccine in healthy adultsMichelle C Crank, Ingelise J Gordon, Galina V Yamshchikov, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Plos One|May 8, 2015
DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trialJulie E Ledgerwood, Abbie R Bellamy, Robert Belshe, et al.
Contemporary Clinical Trials|August 16, 2015
Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boostJulie E Ledgerwood, Zonghui Hu, Pamela Costner, et al.
Plos One|November 16, 2016
Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Michelle C Crank, Eleanor M P Wilson, Laura Novik, et al.
The Journal of Infectious Diseases|September 17, 2014
Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trialUzma N Sarwar, Pamela Costner, Mary E Enama, et al.
The Journal of Infectious Diseases|March 15, 2011
A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trialJulie E Ledgerwood, Theodore C Pierson, Sarah A Hubka, et al.
Vaccine|October 1, 2008
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialJulie E Martin, Mark K Louder, LaSonji A Holman, et al.
Clinical and Vaccine Immunology : CVI|September 22, 2006
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trialJulie E Martin, Nancy J Sullivan, Mary E Enama, et al.
Plos One|September 19, 2019
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trialCristina Carter, Katherine V Houser, Galina V Yamshchikov, et al.
Plos One|November 3, 2018
DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trialKatherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, et al.
Plos One|April 18, 2015
Phase 1 study of pandemic H1 DNA vaccine in healthy adultsMichelle C Crank, Ingelise J Gordon, Galina V Yamshchikov, et al.
Pageof 4